News Image

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Provided By GlobeNewswire

Last update: Jun 3, 2024

PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO).

Read more at globenewswire.com

LIXTE BIOTECHNOLOGY H -CW25

NASDAQ:LIXTW (7/3/2025, 7:44:49 PM)

After market: 0.2013 -0.01 (-6.89%)

0.2162

0 (-1.73%)


LIXTE BIOTECHNOLOGY HOLDINGS

NASDAQ:LIXT (7/3/2025, 7:44:49 PM)

After market: 2.36 -0.47 (-16.61%)

2.83

+0.81 (+40.1%)



Find more stocks in the Stock Screener

Follow ChartMill for more